Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Arrowhead Pharmaceuticals Inc (ARWR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Arrowhead Pharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
23.13 +1.01    +4.57%
29/04 - Closed. Currency in USD ( Disclaimer )
After Hours
23.80
+0.67
+2.90%
18:48:41 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,165,733
  • Bid/Ask: 22.73 / 23.85
  • Day's Range: 22.15 - 23.47
Arrowhead Pharma 23.13 +1.01 +4.57%

NASDAQ:ARWR Financials

 
A brief overview of the NASDAQ:ARWR financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Arrowhead over time.

Arrowhead Pharmaceuticals, Inc. reported earnings results for the first quarter ended December 31, 2023. For the first quarter, the company reported sales was USD 3.55 million compared to USD 62.55 million a year ago. Net loss was USD 132.86 million compared to USD 41.33 million a year ago. Basic loss per share from continuing operations was USD 1.24 compared to USD 0.39 a year ago. Diluted loss per share from continuing operations was USD 1.24 compared to USD 0.39 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ARWR Income Statement

Gross margin TTM 100%
Operating margin TTM -164.75%
Net Profit margin TTM -163.32%
Return on Investment TTM -39.7%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 3.55 16.1 15.82 146.27
Gross Profit 3.55 16.1 15.82 146.27
Operating Income -136.54 -108.33 -102.7 48.16
Net Income -132.86 -109.68 -102.95 48.68

ARWR Balance Sheet

Quick Ratio MRQ 3.35
Current Ratio MRQ 3.73
LT Debt to Equity MRQ 170.62%
Total Debt to Equity MRQ 244.55%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 626.29 765.55 795.86 891.31
Total Liabilities 452.57 478.39 413.87 426.2
Total Equity 173.71 287.16 381.98 465.11

ARWR Cash Flow Statement

Cash Flow/Share TTM -1.83
Revenue/Share TTM 1.69
Operating Cash Flow  -184.93%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -117.84 -25.26 -21.45 -31.67
Cash From Investing Activities 64.84 30.51 -9.9 -36.06
Cash From Financing Activities 0.267 0.152 1.8 0.52
Net Change in Cash -52.68 5.56 -29.62 -67.29
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ARWR Comments

Write your thoughts about Arrowhead Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Kuba Wilk
Kuba Wilk Jul 02, 2021 12:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
go buy and hold ;)
Duane Goodson
Duane Goodson Jan 04, 2021 11:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
Jiamin Xu
Jiamin Xu Oct 20, 2020 3:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dilution soon?
ari kelin
ari kelin Oct 20, 2020 3:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i think they just got a ton of $ from their new deal...doesn't mean won't dilute
Imtanis Farah
Imtanis Farah Sep 23, 2020 4:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Going to 69
Imtanis Farah
Imtanis Farah Sep 17, 2020 2:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Target price 76$
Tommy Nguyen
Tommy Nguyen Sep 17, 2020 2:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Upgrade?
Mr MARKET
Mr MARKET Sep 16, 2020 12:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pandemic covid19 Coronavirus has created massive never ever earning opportunities for biotechs pharmaceutical companies products investments...as its 7bn human beings effected need to be protected cured...supposing usd 100 each one spends on vaccines gloves sanitizers masks its huge mount Everest of earnings for biotechs pharma vaccines companies
Mr MARKET
Mr MARKET Sep 16, 2020 12:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
All pharma biotechs to shoot upwards rocket drive like Arrowhead today.....Trump clearly pushing forward indicating Coronavirus stimulus update: Trump suggests he could back bigger relief billhttps://www.cnbc.com/id/106704892?view=story?__source=androidappshare
Imtanis Farah
Imtanis Farah Sep 02, 2020 2:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Go for 57$
Joey Bigreturn
Joey Bigreturn Jun 12, 2020 3:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Go for 20$
Ivan Dimitrov
Ivan Dimitrov Mar 17, 2020 1:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it is a buy now
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email